A cost-minimization analysis of NCIC Clinical Trials Group LY.12: A phase III study of gemcitabine, clexamethasone, and cisplatin (GDP) compared to dexamethasone, cytarabine, and cisplatin (DHAP) for patients with relapsed or refractory aggressive histology non-Hodgkin's lymphoma Conference Paper uri icon

  •  
  • Overview
  •  
  • Research
  •  
  • Additional Document Info
  •  
  • View All
  •  

authors

  • Cheung, MC
  • Mittmann, N
  • Shepherd, L
  • Risebrough, N
  • Imrie, KR
  • Hay, AE
  • Djurfeldt, M
  • Meyer, Ralph
  • Chen, BE
  • Crump, M

publication date

  • September 1, 2013